偶发路易体病与帕金森病的脑脊液、皮肤及下颌下腺α-突触核蛋白种子扩增检测
基于尸检确诊的19例对照、40例偶发路易体病(ILBD)和15例帕金森病(PD)病例,采用RT-QuIC检测下颌下腺、皮肤和脑脊液中的α-突触核蛋白(aSyn)聚集。ILBD中脑脊液敏感性为75.8%,高于下颌下腺(35.1%)和皮肤(37.5%);PD中三种组织敏感性均较高(87.5%–100%),特异性相似。脑脊液aSyn种子扩增检测可能有助于识别前驱期路易体病。
要点
- ILBD中脑脊液aSyn种子扩增敏感性(75.8%)高于下颌下腺和皮肤。
- PD中下颌下腺、皮肤和脑脊液敏感性均高,特异性相似。
- 脑脊液检测可能有助于识别前驱期路易体病,尤其USSLB I–II期。
核心结论
- 在尸检确诊的ILBD中,脑脊液aSyn种子扩增敏感性中等偏高,而下颌下腺和皮肤敏感性较低。
- 在PD中,下颌下腺、皮肤和脑脊液均显示高敏感性,特异性相似,但样本量小。
- 脑脊液aSyn种子扩增检测可能有助于识别前驱期路易体病,尤其USSLB I–II期病例。
研究设计与样本
- 研究纳入AZSAND尸检病例,包括19例对照、40例ILBD和15例PD。
- 对下颌下腺、皮肤和脑脊液样本采用RT-QuIC方法检测aSyn聚集。
- 分析aSyn种子扩增阳性与路易体病统一分期系统(USSLB)的相关性。
主要发现
- ILBD中aSyn种子扩增敏感性:下颌下腺13/37(35.1%),皮肤6/16(37.5%),脑脊液25/33(75.8%)。
- PD中敏感性:下颌下腺7/8(87.5%),皮肤7/8(87.5%),脑脊液10/10(100%)。
- 特异性:脑脊液9/12(75%),皮肤8/9(88.9%),下颌下腺7/9(77.8%)。
- USSLB分期与三种组织aSyn种子扩增阳性相关,脑脊液对I期和II期(IIa和IIb)病例最敏感。
- 20例三种组织均检测的病例中,仅2例下颌下腺阳性而脑脊液阴性,1例皮肤阳性而脑脊液阴性;6例ILBD脑脊液阳性但下颌下腺和皮肤阴性,其中1例为USSLB I期(仅嗅球)。
临床怎么用
- 对于疑似前驱期路易体病,脑脊液aSyn种子扩增检测可能比皮肤或下颌下腺活检更有价值。
- 在PD中,下颌下腺、皮肤和脑脊液检测均可考虑,但需注意样本量小和特异性数据。
局限性
- 研究样本量小,结果仅为初步。
- ILBD中下颌下腺和皮肤样本量有限(分别为37例和16例)。
- 需要更大样本验证脑脊液检测在前驱期路易体病识别中的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Using RT-QuIC seeding assays determine the presence of pathogenic alpha-synuclein (aSyn) aggregates in the submandibular gland (SMG), skin, and CSF from autopsy-confirmed cases of incidental Lewy body disease (ILBD), Parkinson disease (PD), and controls. METHODS: Submandibular gland, skin, and CSF samples from autopsied cases in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) were assayed using RT-QuIC methods. Correlations with the Unified Staging System for Lewy Body Disorders (USSLB) was performed. RESULTS: A total of 19 controls, 40 ILBD, and 15 PD cases were studied. While aSyn seeding assays were positive in all 3 tissues from ILBD cases, the sensitivity was much lower in the SMG (13/37, 35.1%) and skin (6/16, 37.5%) than in CSF (25/33, 75.8%). In PD sensitivity was good in all tissues: SMG (7/8, 87.5%), skin (7/8, 87.5%), and CSF (10/10, 100%), as was specificity in CSF (9/12, 75%), skin (8/9, 88.9%), and SMG (7/9, 77.8%). USSLB stage correlated with aSyn SAA positivity in all 3 tissues with CSF most sensitive to stages I and II (IIa and IIb) cases. In the 20 cases that had all 3 tissues tested only 2 were positive in the SMG but not CSF and one in skin but not CSF. There were 6 ILBD cases that had positive CSF but not SMG or skin, and one of these ILBD cases was USSLB stage I (olfactory bulb only). DISCUSSION: In this small study of autopsy-confirmed ILBD, aSyn seeding assays had moderately high sensitivity (75.8%) in the CSF but not in skin or SMG. In PD, the skin, SMG, and CSF showed high sensitivity, with specificity being similar in all tissues, although sample sizes were small. These results, although preliminary, suggest that detecting aSyn using seeding assays of CSF, but not the skin or SMG, may be valuable for identifying individuals with prodromal Lewy body disease. This is especially true for ILBD cases that often had Lewy bodies in the olfactory bulb only (USSLB Stage I) or in brainstem regions (Stage IIa), suggesting that detecting these cases may require CSF and not biopsies of the skin or SMG.
引用
- Adler CH, Janarthanam C, Serrano GE, et al. Alpha-Synuclein Seed Amplification Assay in CSF, Skin, and Submandibular Gland From Incidental Lewy Body Disease and Parkinson Disease. Neurology. 2026. PMID: 42348807. doi:10.1212/WNL.0000000000218121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。